Skip to main content
UniHealth

Doctor search

Collin M Blakely, MD

Medical Oncology · San Francisco

NPI 1528287174

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
3
1 carrier
Offices
2
Since medical school
19 years
Perelman School of Med at the University of Pennsylvania, 2007

Offices

2 locations · University of California San Francisco · UCSF Medical Group Business Services

Looking this up.

Hospitals listed: Mills-Peninsula Medical Center · UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

3 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Blakely’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

California Medical Board record

Licence A106689 · Current

Licensed to practise in California · since 2009 · expires 2028-06-30 · University of Pennsylvania School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Medical Oncology

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Peninsula Medical Center

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Peninsula Medical Center
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.139BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.242BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.21 (0.27 to 2.15) · 1,258 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.81 (0.51 to 1.1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths155.44 (112.67 to 198.21) · 90 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.5 · 32 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.1 · 82 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10 · 188 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9 · 473 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths14.8 · 342 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.4 · 485 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.9 · 3,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.2 (0 to 0.4) · 6,904 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.21 (0.02 to 0.4) · 7,052 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.41 (1.43 to 5.39) · 1,695 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.72 (0.17 to 3.28) · 665 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.11 (0.66 to 3.56) · 1,545 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.1 (1.3 to 12.9) · 670 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.96 (2.63 to 9.29) · 653 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.15 to 3.08) · 418 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.14 (0 to 0.78) · 5,539 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.7 · 192 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.215No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.263No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.74No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.3 · 300 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19 · 702 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits1.2 · 207 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-13.6 · 531 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits24.3 · 343 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.1 · 449 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4.5 (2.8 to 7) · 85 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits9.6 (6.7 to 13.7) · 85 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.7 · 189 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits11 · 45 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.6 · 117 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13 (9.7 to 17.2) · 584 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.7 to 1.2) · 764 casesNo differentJan 2024 – Dec 2024

What patients said (523 patients answered, 27% of those asked)

Patient survey stars by topic at Peninsula Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness3
Recommend hospital5
Share of patients giving the best answer at Peninsula Medical Center
Room was "always" clean76%
Nurses "always" communicated well81%
Doctors "always" communicated well80%
Staff "always" explained58%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully79%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)75%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night54%
"YES", patients would definitely recommend the hospital78%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$33,200

Medicare paid this office $33,200 for 80 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)53$21,305$125
Return visit (30+ min)36$3,941$80
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's72$3,149$15
New patient visit (60+ min)13$1,656$127

Who their Medicare patients are

80 Original Medicare patients in 2024. Average age 74 · Women 74% · Also on Medicaid 16% · Health risk score 2.68. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: Cancer 75% · High blood pressure 61% · Coronary heart disease 24% · COPD 21% · Depression 21% · Diabetes 19% · Chronic kidney disease 16% · Atrial fibrillation 15%.

The office billed $226,825, Medicare allowed $43,605 and paid $33,200; for 1,016 services of 22 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024801,016742.68$226,825$33,200
202392856732.61$416,706$40,352
202292316722.09$196,337$30,887
202196295732.51$195,014$30,991
202078258722.45$172,005$21,750
201994268722.44$205,230$25,838
2018102298722.30$212,424$27,122
2017106344722.41$236,573$32,491
201699386732.35$239,362$33,815
201570266722.08$165,094$23,133
201441171742.04$111,761$15,663
20132442751.32$29,206$4,228

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Original Medicare services billed in 2023
Long return visit (40+ min)42$16,826$125
Return visit (30+ min)58$8,543$81
New patient visit (60+ min)21$3,261$155

2022: 3 services

Original Medicare services billed in 2022
Long return visit (40+ min)41$13,155$122
Return visit (30+ min)65$9,901$81
New patient visit (60+ min)14$2,039$146

2021: 4 services

Original Medicare services billed in 2021
Long return visit (40+ min)49$13,942$127
Return visit (30+ min)54$9,729$86
New patient visit (60+ min)21$3,493$166
Short return visit (20+ min)23$1,304$54

2020: 2 services

Original Medicare services billed in 2020
Long return visit (40+ min)51$12,485$95
Return visit (30+ min)51$6,174$69

2019: 2 services

Original Medicare services billed in 2019
Long return visit (40+ min)82$22,415$97
New patient visit (60+ min)18$2,576$143

2018: 3 services

Original Medicare services billed in 2018
Long return visit (40+ min)86$20,242$92
Return visit (30+ min)26$3,427$66
New patient visit (60+ min)20$2,980$149

2017: 4 services

Original Medicare services billed in 2017
Long return visit (40+ min)85$24,131$98
New patient visit (60+ min)28$3,563$127
Return visit (30+ min)36$3,226$63
New patient visit (45+ min)12$1,268$106

2016: 4 services

Original Medicare services billed in 2016
Long return visit (40+ min)43$15,947$99
Return visit (30+ min)49$8,579$68
New patient visit (60+ min)35$5,256$150
Short return visit (20+ min)27$1,832$44

2015: 5 services

Original Medicare services billed in 2015
Long return visit (40+ min)35$10,712$97
Return visit (30+ min)37$5,556$69
New patient visit (60+ min)34$5,080$149
Short return visit (20+ min)16$1,043$45
Office for the evaluation and management of established patient that may not require presence of healthcare professional12$99$8

2014: 3 services

Original Medicare services billed in 2014
Long return visit (40+ min)24$10,575$99
New patient visit (60+ min)23$3,066$133
Return visit (30+ min)17$1,557$62

2013: 2 services

Original Medicare services billed in 2013
New patient visit (60+ min)13$1,875$144
Long return visit (40+ min)11$1,727$91

Drugs they prescribed that Part D paid

$2,954,344

Pharmacies billed $2,954,344 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

70 generic and 181 brand-name prescriptions · $2,954,344 in drug cost · 17 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Tagrisso102$1,797,694$17,624
Lorbrena30$659,524$21,984
Xalkori12$269,365$22,447
Eliquis20$11,712$586
Dexamethasone13$486$37
See all 6 drugs
Every Part D drug this clinician prescribed
Tagrisso102$1,797,694$17,624
Lorbrena30$659,524$21,984
Xalkori12$269,365$22,447
Eliquis20$11,712$586
Dexamethasone13$486$37
Furosemide15$44$3

Year by year

Part D prescribing by year
202425138None72%$2,954,344
2023270370% (0)76%$3,112,850
202224742None75%$2,782,476
202121537None63%$1,772,429
202015328None58%$973,642
201916234None41%$638,809
201822737None34%$624,692
201720634None47%$595,682
201624336None43%$765,759
201523336NoneNone$343,180
20141511813% (19)30%$229,124

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 6 drugs

Part D drugs prescribed in 2023
Tagrisso136$2,265,822$16,660
Lorbrena16$320,359$20,022
Xalkori12$254,203$21,184
Eliquis27$16,581$614
Erlotinib15$14,438$963
Ondansetron11$122$11

2022: 5 drugs

Part D drugs prescribed in 2022
Tagrisso119$1,904,070$16,001
Lorbrena24$443,081$18,462
Xalkori14$273,276$19,520
Lamivudine Hbv11$765$70
Amlodipine Besylate12$135$11

2021: 6 drugs

Part D drugs prescribed in 2021
Tagrisso86$1,367,506$15,901
Lorbrena14$256,821$18,344
Eliquis16$11,433$715
Ondansetron16$582$36
Dexamethasone11$242$22
Prochlorperazine Maleate18$183$10

2020: 4 drugs

Part D drugs prescribed in 2020
Tagrisso55$876,727$15,940
Eliquis12$5,479$457
Clindamycin Phosphate15$230$15
Furosemide11$20$2

2019: 6 drugs

Part D drugs prescribed in 2019
Tagrisso28$435,730$15,562
Lorbrena12$100,193$8,349
Dexamethasone12$421$35
Ondansetron19$356$19
Prochlorperazine Maleate16$118$7
Lorazepam16$50$3

2018: 7 drugs

Part D drugs prescribed in 2018
Tagrisso26$396,711$15,258
Tarceva21$160,723$7,653
Ondansetron24$714$30
Dexamethasone19$629$33
Prochlorperazine Maleate34$233$7
Levothyroxine12$163$14
Lorazepam24$162$7

2017: 6 drugs

Part D drugs prescribed in 2017
Tarceva47$302,026$6,426
Tagrisso17$235,912$13,877
Xarelto16$6,536$409
Ondansetron30$386$13
Dexamethasone14$210$15
Prochlorperazine Maleate21$137$7

2016: 8 drugs

Part D drugs prescribed in 2016
Tagrisso24$331,741$13,823
Tarceva42$286,493$6,821
Xarelto12$4,471$373
Prochlorperazine Maleate27$207$8
Ondansetron17$165$10
Dexamethasone13$134$10
Lorazepam15$100$7
Metformin Hcl Er11$27$2

2015: 7 drugs

Part D drugs prescribed in 2015
Tarceva35$228,759$6,536
Gilotrif11$74,990$6,817
Clindamycin Phosphate11$693$63
Ondansetron19$499$26
Dexamethasone27$263$10
Prochlorperazine Maleate16$109$7
Lorazepam20$99$5

2014: 4 drugs

Part D drugs prescribed in 2014
Tarceva27$203,864$7,551
Clindamycin Phosphate16$1,098$69
Lidocaine Hcl Viscous13$120$9
Lorazepam17$85$5

Money from drug and device companies

$4,952 in 2025

Industry payments by year
202544$4,890$4,952
2024613$11,625$13,044
202347$5,350$23,625
202233$3,628$22,378
202111$560$560
202059$10,525$10,640
2019616$5,323$5,512

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
PfizerLorbrena$2,520
1 payment
  • Consulting for Lorbrena · 2025-06-20 · $2,520
Janssen BiotechRybrevant$1,670
1 payment
  • Consulting for Rybrevant · 2025-11-06 · $1,670
Taiho OncologyNone$700
1 payment
  • Paid to speak or teach · 2025-04-30 · $700
Daiichi SankyoDatroway$62
1 payment
  • Education for Datroway · 2025-02-07 · $62
See all 4 published payments
Every published payment
Janssen BiotechConsulting · 2025-11-06Rybrevant$1,670
PfizerConsulting · 2025-06-20Lorbrena$2,520
Taiho OncologyPaid to speak or teach · 2025-04-30None$700
Daiichi SankyoEducation · 2025-02-07Datroway$62
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $13,044

Payments by company in 2024
Taiho OncologyNone$5,485
7 payments
  • Travel · 2024-10-31 · $67
  • Paid to speak or teach · 2024-10-31 · $1,200
  • Travel · 2024-10-31 · $252
  • Paid to speak or teach · 2024-09-30 · $3,000
  • Travel · 2024-09-30 · $129
  • Meals · 2024-09-30 · $144
  • Travel · 2024-08-15 · $694
Takeda Pharmaceuticals U.S.A.Alunbrig$2,700
1 payment
  • Consulting for Alunbrig · 2024-04-02 · $2,700
Janssen Scientific AffairsNone$1,875
1 payment
  • Consulting · 2024-08-02 · $1,875
PfizerLorbrena$1,709
2 payments
  • Consulting for Lorbrena · 2024-03-18 · $1,575
  • Meals for Lorbrena · 2024-02-22 · $134
E.R. Squibb & Sons L.L.C.None$650
1 payment
  • Consulting · 2024-01-11 · $650
GenentechNone$625
1 payment
  • Consulting · 2024-02-13 · $625

2023: $23,625

Payments by company in 2023
GenentechNone$18,182
1 payment
  • Grant · 2023-06-30 · $18,182
Gilead SciencesTrodelvy$2,713
3 payments
  • Consulting for Trodelvy · 2023-09-29 · $760
  • Consulting for Trodelvy · 2023-06-07 · $1,890
  • Meals for Trodelvy · 2023-06-04 · $63
Bayer Healthcare PharmaceuticalsVitrakvi$1,400
1 payment
  • Consulting for Vitrakvi · 2023-06-28 · $1,400
E.R. Squibb & Sons L.L.C.None$1,330
2 payments
  • Consulting · 2023-10-25 · $1,300
  • Meals · 2023-09-30 · $30

2022: $22,378

Payments by company in 2022
GenentechNone$18,750
1 payment
  • Grant · 2022-06-30 · $18,750
Janssen BiotechNone$1,860
1 payment
  • Consulting · 2022-01-14 · $1,860
Janssen Scientific AffairsRybrevant$1,768
1 payment
  • Consulting for Rybrevant · 2022-05-12 · $1,768

2021: $560

Payments by company in 2021
Blueprint MedicinesNone$560
1 payment
  • Honoraria · 2021-04-30 · $560

2020: $10,640

Payments by company in 2020
AmgenNone$6,325
4 payments
  • Consulting · 2020-11-25 · $3,300
  • Consulting · 2020-11-25 · $825
  • Consulting · 2020-10-09 · $1,100
  • Consulting · 2020-06-12 · $1,100
Bayer HealthCare PharmaceuticalsVitrakvi$2,100
1 payment
  • Consulting for Vitrakvi · 2020-12-03 · $2,100
Blueprint MedicinesNone$1,400
1 payment
  • Honoraria · 2020-06-09 · $1,400
Foundation MedicineFoundationone Liquid$700
2 payments
  • Consulting for Foundationone Liquid · 2020-04-17 · $350
  • Consulting for Foundationone Liquid · 2020-03-13 · $350
AstraZeneca Pharmaceuticals LPNone$115
1 payment
  • Meals · 2020-02-21 · $115

2019: $5,512

Payments by company in 2019
F. Hoffmann-La Roche AGNon-Covered Product$4,360
9 payments
  • Paid to speak or teach for Non-Covered Product · 2019-12-31 · $367
  • Paid to speak or teach for Non-Covered Product · 2019-12-31 · $1,235
  • Paid to speak or teach for Non-Covered Product · 2019-09-30 · $351
  • Paid to speak or teach for Non-Covered Product · 2019-09-30 · $425
  • Paid to speak or teach for Non-Covered Product · 2019-09-30 · $1,125
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $209
  • Paid to speak or teach for Non-Covered Product · 2019-06-30 · $282
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $200
  • Paid to speak or teach for Non-Covered Product · 2019-03-31 · $167
Foundation MedicineFoundationone Liquid$963
3 payments
  • Consulting for Foundationone Liquid · 2019-12-12 · $263
  • Consulting for Foundationone Liquid · 2019-12-05 · $350
  • Consulting for Foundationone Liquid · 2019-10-03 · $350
Eli Lilly andNone$148
1 payment
  • Meals · 2019-03-08 · $148
AstraZeneca Pharmaceuticals LPNone$26
1 payment
  • Meals · 2019-02-22 · $26
PfizerLorbrena$11
1 payment
  • Education for Lorbrena · 2019-10-31 · $11
Genentech USATecentriq$4
1 payment
  • Meals for Tecentriq · 2019-07-23 · $4

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Novartis Pharmaceuticals Corporation · A Phase I/II Study of Capmatinib Plus Trametinib in Patients With Metastatic Met Exon 14 Skipping Mutation Positive Nsclc · 2023Their institution$1,362,275
AstraZeneca Pharmaceuticals LP · A Phase II Study To Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable Egfr-Mutant Non-Small Cell Lung Cancer · 2019Their institution$982,464
AstraZeneca Pharmaceuticals LP · A Phase II Study To Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable Egfr-Mutant Non-Small Cell Lung Cancer · 2022Their institution$763,663
Takeda Pharmaceuticals U.S.A., Inc. · A Phase I Study of Brigatinib With Binimetinib in Advanced Alk- Or Ros1-Rearranged Non-Small Cell Lung Cancer (Nsclc) · 2021Their institution$544,408
Novartis Pharmaceuticals Corporation · A Phase I/II Study of Capmatinib Plus Trametinib in Patients With Metastatic Met Exon 14 Skipping Mutation Positive Nsclc · 2022Their institution$385,647
AstraZeneca Pharmaceuticals LP · A Phase II Study To Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable Egfr-Mutant Non-Small Cell Lung Cancer · 2021Their institution$375,611
AstraZeneca Pharmaceuticals LP · A Phase II Study To Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable Egfr-Mutant Non-Small Cell Lung Cancer · 2024Their institution$309,655
Takeda Pharmaceuticals U.S.A., Inc. · A Phase I/Ib Study of Alisertib in Combination With Osimertinib in Metastatic Egfr-Mutant Lung Cancer. · 2020Their institution$290,239
AstraZeneca Pharmaceuticals LP · A Phase II Study To Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable Egfr-Mutant Non-Small Cell Lung Cancer · 2020Their institution$284,800
Novartis Pharmaceuticals Corporation · A Phase I II Study of Ceritinib Trametinib in Patients With Advanced Alk Positive Nsclc · 2019Their institution$269,809
Novartis Pharmaceuticals Corporation · A Phase I II Study of Ceritinib Trametinib in Patients With Advanced Alk Positive Nsclc · 2020Their institution$262,984
PUMA BIOTECHNOLOGY, INC. · Alisertib in Combination With Osimertinib in Metastatic Egfr Mutant Lung Cancer · 2023Their institution$221,274
Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2019Their institution$181,284
Novartis Pharmaceuticals Corporation · Phase II Trial of Ceritinib in Combination With Stereotactic Ablative Radiation Sabr in Alk Rearranged Metastatic Lung Adenocarcinoma · 2021Their institution$160,230
PFIZER INC. · A Phase I Study of Brigatinib With Binimetinib in Advanced Alk Or Ros1rearranged Nonsmall Cell Lung Cancer Nsclc · 2022Their institution$131,214
AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2023Their institution$129,802
Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2021Their institution$121,336
Mirati Therapeutics, Inc. · A Phase 2 Trial of Mrtx849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With Kras G12c Mutation · 2023Their institution$118,262
PFIZER INC. · A Phase I Study of Brigatinib With Binimetinib in Advanced Alk Or Ros1rearranged Nonsmall Cell Lung Cancer Nsclc · 2021Their institution$111,936
Mirati Therapeutics, Inc. · A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and A Phase 3 Trial of Adagrasib in Combination · 2024Their institution$106,539
Genentech, Inc. · A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divaras · 2025Their institution$102,284
PUMA BIOTECHNOLOGY, INC. · Alisertib in Combination With Osimertinib in Metastatic Egfr-Mutant Lung Cancer · 2024Their institution$92,198
Mirati Therapeutics, Inc. · A Phase 2 Trial of Mrtx849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With Kras G12c Mutation · 2025Their institution$84,962
Takeda Pharmaceuticals U.S.A., Inc. · A Phase I Study of Brigatinib With Binimetinib in Advanced Alk- Or Ros1-Rearranged Non-Small Cell Lung Cancer (Nsclc) · 2022Their institution$80,942
Novartis Pharmaceuticals Corporation · A Phase I/II Study of Capmatinib Plus Trametinib in Patients With Metastatic Met Exon 14 Skipping Mutation Positive Nsclc · 2024Their institution$71,024
AstraZeneca Pharmaceuticals LP · A Phase II Study To Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable Egfr-Mutant Non-Small Cell Lung Cancer · 2023Their institution$68,518
AstraZeneca Pharmaceuticals LP · An Open-Label Window of Opportunity Trial To Evaluate the Effect of Durvalumab (D) and Tremelimumab (T) With Platinum-Based Chemotherapy (Gemcis) in Intrahepatic Cholangiocarcinoma (Icc) · 2023Their institution$67,543
Novartis Pharmaceuticals Corporation · A Phase I II Study of Ceritinib Trametinib in Patients With Advanced Alk Positive Nsclc · 2022Their institution$64,482
AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2024Their institution$64,104
AstraZeneca Pharmaceuticals LP · Multiarm Open Label Multicenter Phase 1b 2 Study To Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced Egfrm Nsclc · 2019Their institution$57,174
AstraZeneca Pharmaceuticals LP · Multiarm Open Label Multicenter Phase 1b 2 Study To Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced Egfrm Nsclc · 2020Their institution$53,261
AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2023Their institution$51,749
Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2020Their institution$51,123
Novartis Pharmaceuticals Corporation · Phase II Trial of Ceritinib in Combination With Stereotactic Ablative Radiation Sabr in Alk Rearranged Metastatic Lung Adenocarcinoma · 2022Their institution$45,119
AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2022Their institution$44,434
Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2023Their institution$40,049
F. Hoffmann-La Roche AG · Nautika1 Previously Lcmc4 · 2024Their institution$35,588
Novartis Pharmaceuticals Corporation · A Phase I II Study of Ceritinib Trametinib in Patients With Advanced Alk Positive Nsclc · 2021Their institution$35,200
AstraZeneca Pharmaceuticals LP · Phase III Study Non Small Cell Lung Cancer (Nsclc) Adaura2, Nct05120349, 2021-004135-89, Tagrisso · 2022Their institution$34,760
Novartis Pharmaceuticals Corporation · A Phase II Trial To Evaluate Trametinib in Molecular Subpopulation of Patients With Advanced Nonsmalllung Cancer · 2019Their institution$33,147
AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2024Their institution$31,926
Novartis Pharmaceuticals Corporation · Phase II Trial of Ceritinib in Combination With Stereotactic Ablative Radiation Sabr in Alk Rearranged Metastatic Lung Adenocarcinoma · 2019Their institution$30,637
Genentech, Inc. · Master A136751 Task Order Genetic and Epigenetic Resist · 2021Their institution$30,000
Takeda Pharmaceuticals U.S.A., Inc. · A Phase I Study of Brigatinib With Binimetinib in Advanced Alk- Or Ros1-Rearranged Non-Small Cell Lung Cancer (Nsclc) · 2023Their institution$29,758
Mirati Therapeutics, Inc. · A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With Kras G12c Mutatio · 2025Their institution$28,536
Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2022Their institution$27,087
Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2024Their institution$23,001
Mirati Therapeutics, Inc. · 849vs1 Verastem P1/2 Adagrasib + Vs-6766 Combo · 2023Their institution$20,959
AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2025Their institution$18,073
AstraZeneca Pharmaceuticals LP · A Phase III Double-Blind Randomised Placebo-Controlled International Study To Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With Egfr Mutation Positive Stage Ia2-Ia3 Non-Small Cell Lung Cancer Following Complete Tumour Resection · 2024Their institution$17,921
Mirati Therapeutics, Inc. · A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression on Or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy Sapphire · 2023Their institution$17,363
Genentech, Inc. · Nautika1 Previously Lcmc4 · 2024Their institution$16,804
AstraZeneca Pharmaceuticals LP · A Phase 1, 2 Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Medi4736 in Subjects With Advanced Solid Tumors · 2020Their institution$15,344
Spectrum Pharmaceuticals Inc. · A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (Nsclc), Locally Advanced Or Metastatic, With Egfr Or Her2 Exon 20 Insertion Mutation (Zenith20) · 2023Their institution$15,265
AstraZeneca Pharmaceuticals LP · Multiarm Open Label Multicenter Phase 1b 2 Study To Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced Egfrm Nsclc · 2021Their institution$12,833
Blueprint Medicines Corporation · 2023Their institution$10,500
NOVARTIS PHARMACEUTICALS CORPORATION · Research Related Publications Support · 2019This clinician$9,425
Novartis Pharmaceuticals Corporation · Phase II Trial of Ceritinib in Combination With Stereotactic Ablative Radiation Sabr in Alk Rearranged Metastatic Lung Adenocarcinoma · 2024Their institution$9,317
Mirati Therapeutics, Inc. · A Phase 1/2 Study of Avutometinib (Vs-6766) in Combination With Adagrasib in Patients With Kras G12c Mutant Non-Small Cell Lung Cancer (Nsclc) (Ramp 204) · 2024Their institution$7,744
Incyte Corporation · An Open Label Phase 1/2 Study of Incb039110 in Combination With Osimertinib in Subjects With Locally Advanced Or Metastatic Non Small Cell Lung Cancer · 2020Their institution$6,810
Incyte Corporation · An Open Label Phase 1/2 Study of Incb039110 in Combination With Osimertinib in Subjects With Locally Advanced Or Metastatic Non Small Cell Lung Cancer · 2024Their institution$6,525
Genentech, Inc. · 2024Their institution$6,250
AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2025Their institution$4,938
Novartis Pharmaceuticals Corporation · A Phase II Trial To Evaluate Trametinib in Molecular Subpopulation of Patients With Advanced Nonsmalllung Cancer · 2020Their institution$1,966
F. Hoffmann-La Roche AG · Startrk 2 Rxdx 101 02, Alka Alka 372 001 and Startrk 1 Rxdx 101 01 · 2020This clinician$872
F. Hoffmann-La Roche AG · Nautika1 Previously Lcmc4 · 2025This clinician$557
AstraZeneca Pharmaceuticals LP · A Phase III Double-Blind Randomised Placebo-Controlled International Study To Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With Egfr Mutation Positive Stage Ia2-Ia3 Non-Small Cell Lung Cancer Following Complete Tumour Resection · 2023Their institution$350
F. Hoffmann-La Roche AG · Open Label Dose Escalation and Expansion Study of Entrectinib Rxdx 101 in Children, Startrk 2 Rxdx 101 02, Alka Alka 372 001 and Startrk 1 Rxdx 101 01 · 2020This clinician$266
F. Hoffmann-La Roche AG · A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib Rxdx-101 in Children and Adolescents With Recurrent Or Refractory Solid Tumors and Primary Cns Tumors, With Or Without Trk, Ros1, Or Alk Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced Or Metastatic Solid Tumors That Harbor Ntrk123, Ros1, Or Alk Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib Rxdx-101 in Adult · 2020This clinician$260
Spectrum Pharmaceuticals Inc. · Spi-Poz-202 · 2019Their institution$150
Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2025Their institution$133
E.R. Squibb & Sons, L.L.C. · A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy Vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer With Kras G12c Mutation (Krystal-4) · 2025Their institution$89
Genentech, Inc. · Nautika1 Previously Lcmc4 · 2025Their institution$67

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
75.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1528287174
Licence
CA A106689, PA MT190228California A106689: Current · expires 2028-06-30
Trained
Perelman School of Med at the University of Pennsylvania, 2007 · 19 years ago
Group
University of California San Francisco · UCSF Medical Group Business Services
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RH0003X (207RH0003X); Internal medicine (207R00000X)
Mailing address
505 Parnassus Ave, Moffit M1286, San Francisco, CA, 94143
NPI first listed
2007-04-24
NPI last updated
2009-06-16

This is when the NPI record was last certified, not a medical board exam.